Molecular Partners (NASDAQ:MOLN) Trading 6.4% Higher – Here’s Why

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN)’s stock price was up 6.4% during trading on Monday . The stock traded as high as $4.25 and last traded at $4.18. Approximately 6,088 shares were traded during mid-day trading, an increase of 117% from the average daily volume of 2,802 shares. The stock had previously closed at $3.93.

Wall Street Analyst Weigh In

Several brokerages have weighed in on MOLN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research report on Wednesday, July 8th. HC Wainwright reissued a “buy” rating on shares of Molecular Partners in a report on Monday, July 6th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $8.38.

Molecular Partners Trading Up 6.4%

The firm has a market cap of $168.79 million, a PE ratio of -2.15 and a beta of 1.08. The company has a 50-day simple moving average of $3.97 and a 200 day simple moving average of $4.23.

Molecular Partners (NASDAQ:MOLN) last posted its earnings results on Monday, May 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). On average, equities analysts expect that Molecular Partners AG Sponsored ADR will post -1.28 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by hedge funds and other institutional investors.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.